HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway
Abstract
:1. Introduction
2. Results
2.1. Loss of HDAC4 Following Cisplatin Treatment of Gastric Cancer Cells
2.2. miR-140 Partly Mediates Cisplatin-Induced HDAC4 Repression
2.3. Expression Level of HDAC4 Impacts on Cisplatin Cytotoxicity
2.4. Gastric Cancers Harbor HDAC4 Alterations that Impact on Patient Survival
2.5. HDAC4 Regulates Proapoptotic Pathway, Including p53 and TAp73 Expression in Gastric Cancer Cells
2.6. HDAC4 Inhibits BIK and Other Proapoptotic Genes’ Expressions in Gastric Cancer Cells: Role of p53
3. Discussion
4. Materials and Methods
4.1. Biological Materials
4.2. Cell survival Assay
4.3. Isobologram Assay
4.4. Quantitative RT-PCR
4.5. Western Blot Analyses
4.6. Transfection
4.7. Microarrays Analysis and TCGA Analyses
4.8. Xenografts
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Mihmanli, M.; Ilhan, E.; Idiz, U.O.; Alemdar, A.; Demir, U. Recent developments and innovations in gastric cancer. World J. Gastroenterol. 2016, 22, 4307–4320. [Google Scholar] [CrossRef]
- Florea, A.M.; Busselberg, D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3, 1351–1371. [Google Scholar] [CrossRef]
- Huang, D.; Duan, H.; Huang, H.; Tong, X.; Han, Y.; Ru, G.; Qu, L.; Shou, C.; Zhao, Z. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci. Rep. 2016, 6, 20502. [Google Scholar] [Green Version]
- Pietrantonio, F.; de Braud, F.; da Prat, V.; Perrone, F.; Pierotti, M.A.; Gariboldi, M.; Fanetti, G.; Biondani, P.; Pellegrinelli, A.; Bossi, I.; et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013, 33, 1257–1266. [Google Scholar]
- Grabsch, H.I.; Tan, P. Gastric cancer pathology and underlying molecular mechanisms. Dig. Surg. 2013, 30, 150–158. [Google Scholar] [CrossRef]
- Mahu, C.; Purcarea, A.P.; Gheorghe, C.M.; Purcarea, M.R. Molecular events in gastric carcinogenesis. J. Med. Life 2014, 7, 375–378. [Google Scholar]
- Rivlin, N.; Brosh, R.; Oren, M.; Rotter, V. Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. Genes Cancer 2011, 2, 466–474. [Google Scholar] [CrossRef]
- Osman, A.A.; Neskey, D.M.; Katsonis, P.; Patel, A.A.; Ward, A.M.; Hsu, T.K.; Hicks, S.C.; McDonald, T.O.; Ow, T.J.; Alves, M.O.; et al. Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Res. 2015, 75, 1205–1215. [Google Scholar] [CrossRef]
- Oren, M.; Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2, a001107. [Google Scholar] [CrossRef]
- Gaiddon, C.; Lokshin, M.; Ahn, J.; Zhang, T.; Prives, C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell Biol. 2001, 21, 1874–1887. [Google Scholar] [CrossRef]
- Arrowsmith, C.H. Structure and function in the p53 family. Cell Death Differ. 1999, 6, 1169–1173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaika, A.I.; El-Rifai, W. The role of p53 protein family in gastrointestinal malignancies. Cell Death Differ. 2006, 13, 935–940. [Google Scholar] [CrossRef] [PubMed]
- Tomkova, K.; Belkhiri, A.; El-Rifai, W.; Zaika, A.I. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res. 2004, 64, 6390–6393. [Google Scholar] [CrossRef] [PubMed]
- Tomkova, K.; El-Rifai, W.; Vilgelm, A.; Kelly, M.C.; Wang, T.C.; Zaika, A.I. The gastrin gene promoter is regulated by p73 isoforms in tumor cells. Oncogene 2006, 25, 6032–6036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vilgelm, A.E.; Hong, S.M.; Washington, M.K.; Wei, J.; Chen, H.; El-Rifai, W.; Zaika, A. Characterization of DeltaNp73 expression and regulation in gastric and esophageal tumors. Oncogene 2010, 29, 5861–5868. [Google Scholar] [CrossRef]
- Ellis, L.; Atadja, P.W.; Johnstone, R.W. Epigenetics in cancer: Targeting chromatin modifications. Mol. Cancer Ther. 2009, 8, 1409–1420. [Google Scholar] [CrossRef] [Green Version]
- Hong, L.; Yang, Z.; Ma, J.; Fan, D. Function of miRNA in controlling drug resistance of human cancers. Curr. Drug Targets 2013, 14, 1118–1127. [Google Scholar] [CrossRef]
- Hagelkruys, A.; Sawicka, A.; Rennmayr, M.; Seiser, C. The biology of HDAC in cancer: The nuclear and epigenetic components. Handb. Exp. Pharmacol. 2011, 206, 13–37. [Google Scholar]
- De Ruijter, A.J.; van Gennip, A.H.; Caron, H.N.; Kemp, S.; van Kuilenburg, A.B. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem. J. 2003, 370, 737–749. [Google Scholar] [CrossRef]
- Mutze, K.; Langer, R.; Becker, K.; Ott, K.; Novotny, A.; Luber, B.; Hapfelmeier, A.; Gottlicher, M.; Hofler, H.; Keller, G. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 2010, 17, 3336–3343. [Google Scholar] [CrossRef]
- Kang, Z.H.; Wang, C.Y.; Zhang, W.L.; Zhang, J.T.; Yuan, C.H.; Zhao, P.W.; Lin, Y.Y.; Hong, S.; Li, C.Y.; Wang, L. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression. PLoS ONE 2014, 9, e98894. [Google Scholar] [CrossRef] [PubMed]
- Juan, L.J.; Shia, W.J.; Chen, M.H.; Yang, W.M.; Seto, E.; Lin, Y.S.; Wu, C.W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 2000, 275, 20436–20443. [Google Scholar] [CrossRef] [PubMed]
- Riquelme, I.; Letelier, P.; Riffo-Campos, A.L.; Brebi, P.; Roa, J.C. Emerging role of miRNAs in the drug resistance of gastric cancer. Int. J. Mol. Sci. 2016, 17, 424. [Google Scholar] [CrossRef] [PubMed]
- Sekar, D.; Krishnan, R.; Thirugnanasambantham, K.; Rajasekaran, B.; Islam, V.I.; Sekar, P. Significance of microRNA 21 in gastric cancer. Clin. Res. Hepatol. Gastroenterol. 2016. [Google Scholar] [CrossRef] [PubMed]
- Ishiguro, H.; Kimura, M.; Takeyama, H. Role of microRNAs in gastric cancer. World J. Gastroenterol. 2014, 20, 5694–5699. [Google Scholar] [CrossRef]
- Kim, Y.K.; Yu, J.; Han, T.S.; Park, S.Y.; Namkoong, B.; Kim, D.H.; Hur, K.; Yoo, M.W.; Lee, H.J.; Yang, H.K.; et al. Functional links between clustered microRNAs: Suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucl. Acids Res. 2009, 37, 1672–1681. [Google Scholar] [CrossRef]
- Takagi, T.; Iio, A.; Nakagawa, Y.; Naoe, T.; Tanigawa, N.; Akao, Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 2009, 77, 12–21. [Google Scholar] [CrossRef]
- Akiyoshi, S.; Fukagawa, T.; Ueo, H.; Ishibashi, M.; Takahashi, Y.; Fabbri, M.; Sasako, M.; Maehara, Y.; Mimori, K.; Mori, M. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br. J. Cancer 2012, 107, 1345–1353. [Google Scholar] [CrossRef]
- Xia, L.; Zhang, D.; Du, R.; Pan, Y.; Zhao, L.; Sun, S.; Hong, L.; Liu, J.; Fan, D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123, 372–379. [Google Scholar] [CrossRef]
- Licona, C.; Spaety, M.E.; Capuozzo, A.; Ali, M.; Santamaria, R.; Armant, O.; Delalande, F.; van Dorsselaer, A.; Cianferani, S.; Spencer, J.; et al. A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. Oncotarget 2016. [Google Scholar] [CrossRef]
- Nogales, V.; Reinhold, W.C.; Varma, S.; Martinez-Cardus, A.; Moutinho, C.; Moran, S.; Heyn, H.; Sebio, A.; Barnadas, A.; Pommier, Y.; et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 2016, 7, 3084–3097. [Google Scholar] [CrossRef] [PubMed]
- Di Giorgio, E.; Brancolini, C. Regulation of class IIa HDAC activities: It is not only matter of subcellular localization. Epigenomics 2016, 8, 251–269. [Google Scholar] [CrossRef] [PubMed]
- Marek, L.; Hamacher, A.; Hansen, F.K.; Kuna, K.; Gohlke, H.; Kassack, M.U.; Kurz, T. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J. Med. Chem. 2013, 56, 427–436. [Google Scholar] [CrossRef] [PubMed]
- Chou, T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58, 621–681. [Google Scholar] [CrossRef]
- Duong, V.; Bret, C.; Altucci, L.; Mai, A.; Duraffourd, C.; Loubersac, J.; Harmand, P.O.; Bonnet, S.; Valente, S.; Maudelonde, T.; et al. Specific activity of class II histone deacetylases in human breast cancer cells. Mol. Cancer Res. 2008, 6, 1908–1919. [Google Scholar] [CrossRef]
- Garattini, S.K.; Basile, D.; Cattaneo, M.; Fanotto, V.; Ongaro, E.; Bonotto, M.; Negri, F.V.; Berenato, R.; Ermacora, P.; Cardellino, G.G.; et al. Molecular classifications of gastric cancers: Novel insights and possible future applications. World J. Gastrointest. Oncol. 2017, 9, 194–208. [Google Scholar] [CrossRef]
- Lopez, I.; Tournillon, A.S.; Martins, R.P.; Karakostis, K.; Malbert-Colas, L.; Nylander, K.; Fahraeus, R. p53-mediated suppression of BiP triggers BIK-induced apoptosis during prolonged endoplasmic reticulum stress. Cell Death Differ. 2017, 24, 1717–1729. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Zhao, Y.; Xia, Q.; Zheng, L.; Liu, L.; Zhao, B.; Shi, J. Nuclear translocation of annexin 1 following oxygen-glucose deprivation-reperfusion induces apoptosis by regulating Bid expression via p53 binding. Cell Death Dis. 2016, 7, e2356. [Google Scholar] [CrossRef]
- Colarossi, L.; Memeo, L.; Colarossi, C.; Aiello, E.; Iuppa, A.; Espina, V.; Liotta, L.; Mueller, C. Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Proteomics Clin. Appl. 2014, 8, 924–931. [Google Scholar] [CrossRef]
- Zeng, L.S.; Yang, X.Z.; Wen, Y.F.; Mail, S.J.; Wang, M.H.; Zhang, M.Y.; Zheng, X.F.; Wang, H.Y. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging 2016, 8, 1236–1249. [Google Scholar] [CrossRef]
- Cohen, A.L.; Piccolo, S.R.; Cheng, L.; Soldi, R.; Han, B.; Johnson, W.E.; Bild, A.H. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. BMC Med. Genom. 2013, 6, 35. [Google Scholar] [CrossRef] [PubMed]
- Shen, Y.F.; Wei, A.M.; Kou, Q.; Zhu, Q.Y.; Zhang, L. Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices. Oncol. Rep. 2016, 35, 948–954. [Google Scholar] [CrossRef] [PubMed]
- Amodio, N.; Stamato, M.A.; Gulla, A.M.; Morelli, E.; Romeo, E.; Raimondi, L.; Pitari, M.R.; Ferrandino, I.; Misso, G.; Caraglia, M.; et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol. Cancer Ther. 2016. [Google Scholar] [CrossRef] [PubMed]
- Vallabhapurapu, S.D.; Noothi, S.K.; Pullum, D.A.; Lawrie, C.H.; Pallapati, R.; Potluri, V.; Kuntzen, C.; Khan, S.; Plas, D.R.; Orlowski, R.Z.; et al. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat. Commun. 2015, 6, 8428. [Google Scholar] [CrossRef]
- Wilson, A.J.; Byun, D.S.; Nasser, S.; Murray, L.B.; Ayyanar, K.; Arango, D.; Figueroa, M.; Melnick, A.; Kao, G.D.; Augenlicht, L.H.; et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol. Biol. Cell 2008, 19, 4062–4075. [Google Scholar] [CrossRef]
- Song, B.; Wang, Y.; Xi, Y.; Kudo, K.; Bruheim, S.; Botchkina, G.I.; Gavin, E.; Wan, Y.; Formentini, A.; Kornmann, M.; et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28, 4065–4074. [Google Scholar] [CrossRef] [Green Version]
- Imbriano, C.; Gurtner, A.; Cocchiarella, F.; di Agostino, S.; Basile, V.; Gostissa, M.; Dobbelstein, M.; del Sal, G.; Piaggio, G.; Mantovani, R. Direct p53 transcriptional repression: In vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell Biol. 2005, 25, 3737–3751. [Google Scholar] [CrossRef]
- Basile, V.; Mantovani, R.; Imbriano, C. DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, via p53 C-terminal lysines. J. Biol. Chem. 2006, 281, 2347–2357. [Google Scholar] [CrossRef]
- Kao, G.D.; McKenna, W.G.; Guenther, M.G.; Muschel, R.J.; Lazar, M.A.; Yen, T.J. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J. Cell Biol. 2003, 160, 1017–1027. [Google Scholar] [CrossRef] [Green Version]
- Gaiddon, C.; de Tapia, M.; Loeffler, J.P. The tissue-specific transcription factor Pit-1/GHF-1 binds to the c-fos serum response element and activates c-fos transcription. Mol. Endocrinol. 1999, 13, 742–751. [Google Scholar] [CrossRef]
- Vidimar, V.; Meng, X.; Klajner, M.; Licona, C.; Fetzer, L.; Harlepp, S.; Hebraud, P.; Sidhoum, M.; Sirlin, C.; Loeffler, J.P.; et al. Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochem. Pharmacol. 2012, 84, 1428–1436. [Google Scholar] [CrossRef] [PubMed]
- Antoine, M.; Gaiddon, C.; Loeffler, J.P. Ca2+/calmodulin kinase types II and IV regulate c-fos transcription in the AtT20 corticotroph cell line. Mol. Cell Endocrinol. 1996, 120, 1–8. [Google Scholar] [CrossRef]
- Benosman, S.; Meng, X.; von Grabowiecki, Y.; Palamiuc, L.; Hritcu, L.; Gross, I.; Mellitzer, G.; Taya, Y.; Loeffler, J.P.; Gaiddon, C. Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. J. Biol. Chem. 2011, 286, 43013–43025. [Google Scholar] [CrossRef] [PubMed]
- Emig, D.; Salomonis, N.; Baumbach, J.; Lengauer, T.; Conklin, B.R.; Albrecht, M. AltAnalyze and DomainGraph: Analyzing and visualizing exon expression data. Nucl. Acids Res. 2010, 38, W755–W762. [Google Scholar] [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Spaety, M.-E.; Gries, A.; Badie, A.; Venkatasamy, A.; Romain, B.; Orvain, C.; Yanagihara, K.; Okamoto, K.; Jung, A.C.; Mellitzer, G.; et al. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers 2019, 11, 1747. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11111747
Spaety M-E, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C, Yanagihara K, Okamoto K, Jung AC, Mellitzer G, et al. HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers. 2019; 11(11):1747. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11111747
Chicago/Turabian StyleSpaety, Marie-Elodie, Alexandre Gries, Amandine Badie, Aina Venkatasamy, Benoit Romain, Christophe Orvain, Kazuyoshi Yanagihara, Koji Okamoto, Alain C. Jung, Georg Mellitzer, and et al. 2019. "HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway" Cancers 11, no. 11: 1747. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11111747